A phase <scp>III</scp> randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the <scp>TEAM</scp>‐<scp>ET</scp> 2·0 trial

Heinz Gisslinger, Christoph Klade, Vera Yablokova et al.|British Journal of Haematology|2019

Cited by 6